MA
RGNX icon

Montag & Associates’s Regenxbio RGNX Stock Holding History

Montag & Associates’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50
Closed -$1K – 983
2022
Q3 		$1K Hold
50
– – ﹤0.01% 846
2022
Q2 		$1K Hold
50
– – ﹤0.01% 807
2022
Q1 		$2K Hold
50
– – ﹤0.01% 789
2021
Q4 		$2K Hold
50
– – ﹤0.01% 804
2021
Q3 		$2K Hold
50
– – ﹤0.01% 801
2021
Q2 		$2K Hold
50
– – ﹤0.01% 794
2021
Q1 		$2K Hold
50
– – ﹤0.01% 796
2020
Q4 		$2K Buy
+50
New +$1.75K ﹤0.01% 771

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Montag & Associates's RGNX Position: Q4 2022 in Review

Montag & Associates sold out of Regenxbio (RGNX) in Q4 2022, closing a stake of 50 shares — an estimated $1K sold.

Montag & Associates first reported a position in RGNX in Q4 2020 and held it in 8 quarters. The position peaked at $2K in Q1 2022. 182 funds tracked by Wall St. Rank hold RGNX as of Q4 2022.

  • Montag & Associates reported no remaining Regenxbio position as of Q4 2022 after selling out during the quarter.
  • Montag & Associates sold 50 Regenxbio shares in Q4 2022, an estimated $1K.
  • Montag & Associates first reported a position in Regenxbio in Q4 2020 and held it in 8 quarters.
  • Montag & Associates's Regenxbio position peaked at $2K in Q1 2022.
  • 182 funds tracked by Wall St. Rank held Regenxbio as of Q4 2022.

Based on Montag & Associates's 13F filing for Q4 2022, filed 2 Feb 2023.